Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies

Susan P. Perrine, Betty Sue Pace, Douglas V. Faller

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Fetal globin (gamma globin; HBG) is normally expressed during fetal life and prevents the clinical manifestations of beta hemoglobinopathies before birth. HBG genes are normally integrated in hematopoietic stem cells in all humans, and are at least partially amenable to reactivation. Inducing expression of fetal globin (HBG) gene expression to 60% to 70% of alpha globin synthesis produces a β-thalassemia trait phenotype, and reduces anemia. Tailoring combinations of therapeutics to patient subsets characterized for quantitative trait loci which modulate basal fetal hemoglobin and erythroid cell survival should provide effective amelioration of clinical symptoms in β-thalassemia and sickle cell disease.

Original languageEnglish (US)
Pages (from-to)233-248
Number of pages16
JournalHematology/Oncology Clinics of North America
Volume28
Issue number2
DOIs
StatePublished - Apr 1 2014

Fingerprint

Fetal Hemoglobin
Hemoglobinopathies
Thalassemia
Globins
gamma-Globins
alpha-Globins
Erythroid Cells
Quantitative Trait Loci
Sickle Cell Anemia
Hematopoietic Stem Cells
Anemia
Cell Survival
Parturition
Phenotype
Gene Expression
Therapeutics
Genes

Keywords

  • Beta-thalassemia
  • Fetal hemoglobin
  • Genetic modifiers
  • Sickle cell disease
  • Stress signaling

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies. / Perrine, Susan P.; Pace, Betty Sue; Faller, Douglas V.

In: Hematology/Oncology Clinics of North America, Vol. 28, No. 2, 01.04.2014, p. 233-248.

Research output: Contribution to journalReview article

@article{1a370dcceaaf45c2858247c7c8e0cc12,
title = "Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies",
abstract = "Fetal globin (gamma globin; HBG) is normally expressed during fetal life and prevents the clinical manifestations of beta hemoglobinopathies before birth. HBG genes are normally integrated in hematopoietic stem cells in all humans, and are at least partially amenable to reactivation. Inducing expression of fetal globin (HBG) gene expression to 60{\%} to 70{\%} of alpha globin synthesis produces a β-thalassemia trait phenotype, and reduces anemia. Tailoring combinations of therapeutics to patient subsets characterized for quantitative trait loci which modulate basal fetal hemoglobin and erythroid cell survival should provide effective amelioration of clinical symptoms in β-thalassemia and sickle cell disease.",
keywords = "Beta-thalassemia, Fetal hemoglobin, Genetic modifiers, Sickle cell disease, Stress signaling",
author = "Perrine, {Susan P.} and Pace, {Betty Sue} and Faller, {Douglas V.}",
year = "2014",
month = "4",
day = "1",
doi = "10.1016/j.hoc.2013.11.009",
language = "English (US)",
volume = "28",
pages = "233--248",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies

AU - Perrine, Susan P.

AU - Pace, Betty Sue

AU - Faller, Douglas V.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Fetal globin (gamma globin; HBG) is normally expressed during fetal life and prevents the clinical manifestations of beta hemoglobinopathies before birth. HBG genes are normally integrated in hematopoietic stem cells in all humans, and are at least partially amenable to reactivation. Inducing expression of fetal globin (HBG) gene expression to 60% to 70% of alpha globin synthesis produces a β-thalassemia trait phenotype, and reduces anemia. Tailoring combinations of therapeutics to patient subsets characterized for quantitative trait loci which modulate basal fetal hemoglobin and erythroid cell survival should provide effective amelioration of clinical symptoms in β-thalassemia and sickle cell disease.

AB - Fetal globin (gamma globin; HBG) is normally expressed during fetal life and prevents the clinical manifestations of beta hemoglobinopathies before birth. HBG genes are normally integrated in hematopoietic stem cells in all humans, and are at least partially amenable to reactivation. Inducing expression of fetal globin (HBG) gene expression to 60% to 70% of alpha globin synthesis produces a β-thalassemia trait phenotype, and reduces anemia. Tailoring combinations of therapeutics to patient subsets characterized for quantitative trait loci which modulate basal fetal hemoglobin and erythroid cell survival should provide effective amelioration of clinical symptoms in β-thalassemia and sickle cell disease.

KW - Beta-thalassemia

KW - Fetal hemoglobin

KW - Genetic modifiers

KW - Sickle cell disease

KW - Stress signaling

UR - http://www.scopus.com/inward/record.url?scp=84896880810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896880810&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2013.11.009

DO - 10.1016/j.hoc.2013.11.009

M3 - Review article

C2 - 24589264

AN - SCOPUS:84896880810

VL - 28

SP - 233

EP - 248

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 2

ER -